Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.

Autor: Atallah E; Medical College of Wisconsin, Milwaukee, WI, USA. eatallah@mcw.edu., Mauro MJ; Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Hochhaus A; Universitätsklinikum Jena, Jena, Germany., Boquimpani C; HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil.; Oncoclínica Centro de Tratamento Oncológico, Rio de Janeiro, Brazil., Minami Y; National Cancer Center Hospital East, Kashiwa, Japan., Maheshwari VK; Novartis Healthcare Pvt. Ltd, Hyderabad, India., Saini L; Novartis Healthcare Pvt. Ltd, Hyderabad, India., Corbin R; Novartis Services Inc., East Hanover, NJ, USA., Réa D; Adult Hematology Hôpital Saint-Louis and FiLMC, Paris, France.
Jazyk: angličtina
Zdroj: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (9), pp. 6247-6262. Date of Electronic Publication: 2023 Jan 28.
DOI: 10.1007/s00432-022-04562-5
Abstrakt: Purpose: The current standard of care for chronic-phase chronic myeloid leukemia (CP-CML) is tyrosine kinase inhibitors (TKIs). Treatment recommendations are unclear for CP-CML failing ≥ 2 lines of treatment, partly due to the paucity of head-to-head trials evaluating TKIs. Thus, matching-adjusted indirect comparisons (MAICs) were conducted to compare asciminib with competing TKIs in third- or later line (≥ 3L) CP-CML.
Methods: Individual patient-level data for asciminib (ASCEMBL; follow-up: ≥ 48 weeks) and published aggregate data for comparator TKIs (ponatinib, nilotinib, and dasatinib) informed the analyses. Major molecular response (MMR), complete cytogenetic response (CCyR), and time to treatment discontinuation (TTD) were assessed, where feasible.
Results: Asciminib was associated with statistically significant improvements in MMR by 6 (relative risk [RR]: 1.55; 95% confidence interval [CI]: 1.02, 2.36) and 12 months (RR: 1.48; 95% CI: 1.03, 2.14) vs ponatinib. For CCyR, the results vs ponatinib were similar by 6 (RR: 1.11; 95% CI: 0.81, 1.52) and 12 months (RR: 0.97; 95% CI: 0.73, 1.28). Asciminib was associated with improvements in MMR by 6 months vs dasatinib but with a CI overlapping one (RR 1.52; 95% CI: 0.66, 3.53). Asciminib was associated with statistically significant improvements in CCyR by 6 (RR: 3.57; 95% CI: 1.42, 8.98) and 12 months (RR: 2.03; 95% CI: 1.12, 3.67) vs nilotinib/dasatinib. Median TTD was unreached for asciminib in ASCEMBL. However, post-adjustment asciminib implied prolonged TTD vs nilotinib and dasatinib, but not vs ponatinib.
Conclusion: These analyses demonstrate favorable outcomes with asciminib versus competing TKIs, highlighting its therapeutic potential in ≥ 3L CP-CML.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: